soul trial oral semaglutide cardiovascular outcomes 2024 nejm results and in Type 2 Diabetes NEJM Editorial Fellow Harleen Marwah,

S.ChungA

Compared to the GLP-1 receptor agonist semaglutide and placebo, tirzepatide demonstrated superior reductions in HbA1c (2.05%) and body weight (11.2kg) over 28 weeks

Grip strength and five-repetition maximum in compound lifts offer additional functional metrics that capture the muscular benefits of improved mitochondrial efficiency and glucose uptake in skeletal muscle

You can look up the lot number on its website

This is an injectable peptide that can be obtained by seeing a physician that specializes in Peptide therapy

Biosimilar development costs $100-300 million per product, takes 5-9 years, and requires a cell line, manufacturing process, and comparability data set built entirely independent of the originator